News Conference News HFSA 2025 Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM Yael L. Maxwell October 01, 2025
News Opinion Off Script Evoque and Patisiran: A Tale of Two Regulatory Journeys Sanjay Kaul, MD March 29, 2024
News Conference News AHA 2023 Seeing Sticker Price for HFrEF Meds Opens Door to Discussions Caitlin E. Cox November 14, 2023
News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020
News Daily News FDA Provides Update on Tainted ARB Investigation, With New Impurity Found Todd Neale March 04, 2019
News Daily News Lack of Short-term Cancer Risk With Tainted Valsartan ‘Reassuring’ Todd Neale September 13, 2018
News Daily News FDA Recalls Valsartan-Containing Drugs After Detection of Carcinogen Michael O'Riordan July 16, 2018